Successful results for phase III study with oral Laquinimod
Posted: Thu Dec 09, 2010 12:29 am
Teva Pharmaceutical Industries Ltd. and Active Biotech announced today initial results from the two-year Phase III ALLEGRO study, which demonstrated that relapsing-remitting multiple sclerosis (MS) patients treated with 0.6 mg daily oral laquinimod experienced a statistically significant reduction in annualized relapse rate compared to placebo.
Additional clinical endpoints, including significant reduction in disability progression, as measured by Expanded Disability Severity Scale (EDSS), were also achieved..... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1735